10,910 Halozyme Therapeutics, Inc. $HALO Shares Bought by Cooper Investors PTY Ltd.

Cooper Investors PTY Ltd. lifted its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 19.8% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 65,933 shares of the biopharmaceutical company’s stock after acquiring an additional 10,910 shares during the period. Halozyme Therapeutics accounts for about 3.9% of Cooper Investors PTY Ltd.’s portfolio, making the stock its 7th largest position. Cooper Investors PTY Ltd.’s holdings in Halozyme Therapeutics were worth $7,279,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of HALO. NorthCrest Asset Manangement LLC grew its holdings in Halozyme Therapeutics by 27.7% in the third quarter. NorthCrest Asset Manangement LLC now owns 57,661 shares of the biopharmaceutical company’s stock worth $6,333,000 after purchasing an additional 12,511 shares during the period. GK Wealth Management LLC bought a new stake in Halozyme Therapeutics in the third quarter valued at $178,000. Balefire LLC raised its holdings in shares of Halozyme Therapeutics by 9.9% during the third quarter. Balefire LLC now owns 3,227 shares of the biopharmaceutical company’s stock valued at $356,000 after purchasing an additional 291 shares during the period. Wedmont Private Capital acquired a new position in shares of Halozyme Therapeutics during the third quarter valued at about $294,000. Finally, Journey Retirement Planning & Investment Management LLC acquired a new position in shares of Halozyme Therapeutics during the third quarter valued at about $332,000. 97.79% of the stock is owned by institutional investors.

Halozyme Therapeutics Stock Down 1.3%

HALO traded down $1.46 during trading on Tuesday, hitting $109.62. 1,772,697 shares of the company’s stock were exchanged, compared to its average volume of 1,931,753. The company has a quick ratio of 2.31, a current ratio of 2.71 and a debt-to-equity ratio of 13.50. The business’s 50 day moving average is $106.78 and its two-hundred day moving average is $83.54. Halozyme Therapeutics, Inc. has a fifty-two week low of $61.22 and a fifty-two week high of $116.85. The stock has a market cap of $12.44 billion, a P/E ratio of 32.72, a PEG ratio of 0.42 and a beta of 0.88.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share for the quarter, beating analysts’ consensus estimates of $1.79 by $0.49. The firm had revenue of $481.00 million for the quarter, compared to analyst estimates of $402.28 million. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The business’s quarterly revenue was up 47.7% compared to the same quarter last year. During the same period last year, the firm earned $1.54 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. As a group, equities analysts expect that Halozyme Therapeutics, Inc. will post 8.25 earnings per share for the current fiscal year.

Analyst Ratings Changes

HALO has been the subject of several research reports. Leerink Partners upgraded Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and raised their target price for the company from $83.00 to $110.00 in a research note on Friday, August 7th. Weiss Ratings raised Halozyme Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research report on Monday, August 31st. HC Wainwright upped their price target on Halozyme Therapeutics from $115.00 to $130.00 and gave the stock a “buy” rating in a research note on Wednesday, October 7th. TD Cowen increased their price target on Halozyme Therapeutics from $105.00 to $130.00 and gave the stock a “buy” rating in a report on Tuesday. Finally, Wells Fargo & Company increased their price target on Halozyme Therapeutics from $75.00 to $95.00 and gave the stock an “equal weight” rating in a report on Friday, August 7th. Nine analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $96.50.

Insider Activity at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Matthew L. Posard sold 18,996 shares of the business’s stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $107.74, for a total transaction of $2,046,629.04. Following the completion of the sale, the director directly owned 58,839 shares of the company’s stock, valued at approximately $6,339,313.86. The trade was a 24.41% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of the stock in a transaction that occurred on Wednesday, September 9th. The stock was sold at an average price of $107.43, for a total value of $2,148,600.00. Following the completion of the sale, the chief executive officer directly owned 767,780 shares of the company’s stock, valued at approximately $82,482,605.40. This trade represents a 2.54% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 125,852 shares of company stock valued at $13,538,046. 2.50% of the stock is owned by corporate insiders.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that improve the administration of injectable medicines. The company’s primary platform, ENHANZE, uses recombinant human hyaluronidase to temporarily modify tissue beneath the skin, allowing certain drugs and biologics that are traditionally delivered by intravenous infusion to be administered by subcutaneous injection.

Halozyme licenses its technology to pharmaceutical and biotechnology companies, which incorporate it into their own therapies.